Pharmaxis anti-fibrotic pipeline review highlights drug with strong pre-clinical data for bone marrow cancer myelofibrosis
Kazia Therapeutics studies evaluate therapeutic candidates in ovarian cancer and brain tumours
Zelda Therapeutics on track to report on multiple clinical trials
Only registered members can use this feature.
Copyright © Proactive Investors 2019.
All Rights Reserved - Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.